tiprankstipranks
Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH

Alterity Therapeutics Ltd. (ATH) Share Price & Analysis

3 Followers

ATH Stock Chart & Stats

Day’s RangeAU$0 - AU$0
52-Week Range― - ―
Previous CloseAU$0.01
Volume11.15M
Average Volume (3M)N/A
Market Cap
AU$31.43M
Enterprise ValueAU$15.86M
Total Cash (Recent Filing)AU$15.77M
Total Debt (Recent Filing)AU$210.38K
Price to Earnings (P/E)-2.0
Beta1.34
Feb 27, 2025
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,416,418,418
10 Day Avg. Volume39,413,027
30 Day Avg. VolumeN/A
Standard Deviation0.33
R-Squared0.01
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.69
Price to Sales (P/S)46.61
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.61%0.00%0.00%99.39%
0.00% Other Institutional Investors
99.39% Public Companies and
Individual Investors

ATH FAQ

What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Currently, no data Available
What is Alterity Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Feb 27, 2025 which is in 308 days.
    How were Alterity Therapeutics Ltd.’s earnings last quarter?
    Alterity Therapeutics Ltd. released its earnings results on Feb 28, 2024. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.002.
      Is Alterity Therapeutics Ltd. overvalued?
      According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Alterity Therapeutics Ltd. pay dividends?
        Alterity Therapeutics Ltd. does not currently pay dividends.
        What is Alterity Therapeutics Ltd.’s EPS estimate?
        Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Alterity Therapeutics Ltd. have?
        Alterity Therapeutics Ltd. has 5,238,018,000 shares outstanding.
          What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
          Alterity Therapeutics Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went up 5%.
            Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
            Currently, no hedge funds are holding shares in AU:ATH
            ---

            Alterity Therapeutics Ltd. Stock Smart Score

            6
            Neutral
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Fundamentals

            Return on Equity
            -52.42%
            Trailing 12-Months
            Asset Growth
            -33.11%
            Trailing 12-Months

            Company Description

            Alterity Therapeutics Ltd.

            Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Alterity Therapeutics Ltd.
            Bristol-Myers Squibb
            Johnson & Johnson
            Pfizer
            Merck & Company
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis